SkyKnight Capital backs Apex Infusion
The California provider operates about 40 ambulatory infusion suites and a home-infusion nursing network, with management retaining a significant stake.
Takeaways
- Apex Infusion is a omnichannel infusion services provider.
- SkyKnight Capital and Apex Infusion are classified as a platform transaction.
- The target serves healthcare across US.
SkyKnight Capital agreed to invest in Apex Infusion, an infusion-services provider founded in 2006.
Apex serves patients through about 40 ambulatory infusion suites and a home-infusion nursing network, offering treatment outside traditional hospital settings.
Apex's clinician-led management team will retain a significant ownership stake, while FFL Partners will remain a minority investor.
SkyKnight said it will support expansion into new markets, partnerships with health systems and payors, and technology initiatives intended to improve patient access.
The transaction is subject to customary closing conditions and regulatory approvals.
Get tomorrow morning's tape in your inbox.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up before the workday starts.